BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Receives Consensus Rating of "Moderate Buy" from Brokerages
MarketBeat
BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) has received a "Moderate Buy" consensus rating from six analysts, with an average 12-month price target of $35.00. This comes despite the company missing its quarterly EPS estimate significantly, reporting -$8.75 against a consensus of -$0.84. Insider buying activity was strong, with company insiders acquiring 1.57 million shares worth approximately $25.2 million in the last quarter, including notable purchases by Orbimed Advisors and Bihua Chen at $1
Read the full story
This is a short summary. The complete article is published by MarketBeat.
Headline and summary aggregated from public news feeds. For information only — not financial advice.